Inflammatory Bowel Disease (Crohn's and Ulcerative Colitis)Life Extension Suggestions
Abd-Allah AR et al. Pro-inflammatory and oxidative stress pathways which compromise sperm motility and survival may be altered by L-carnitine. Oxid Med Cell Longev. 2009 Apr-Jun;2(2):73-81.
Abitbol V et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther. 2002 May;16(5):919-27.
Abraham C and Cho JH. Inflammatory bowel disease. N Engl J Med. 2009 Nov 19;361(21):2066-78.
Aghdassi E, Wendland BE, et al. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol. 2003 Feb;98(2):348-53.
Agrawal M et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep. 2011 Dec;9(4):251-7.
Alastair F et al. Nutrition in inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2011 Sep;35(5):571-80. Epub 2011 Aug 8.
Almallah YZ et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998 May;93(5):804-9.
Almeiner HA, Al Menshawy HH, Maher MM, Al Gamal S. Oxidative stress and inflammatory bowel disease. Front Biosci 2012;E4:1335-44.
Andus T, Klebl F, et al. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther. 2003 Feb;17(3):409-14.
Aratari A, Papi C, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liv Dis 2008;40:821-6.
Aslan A et al. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992 Apr;87(4):432-7.
Assisi RF; GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol 2008;54(3):231-8.
Axelsson C and Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand J Gastroenterol. 1977;12(1):89-95.
Azcarate-Peril Ma et al. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G401-24. Epub 2011 Jun 23.
Barclay GR, McKenzie H, et al. The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol 1992;27:196-200.
Bartel G, Weiss I, et al. Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm Bowel Dis 2008;14:374-82.
Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther. 2004 Jul 15;20(2):151-9.
Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database System Rev 2008;(1):CD006893.
Belli DC et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988 Mar;94(3):603-10.
Belluzzi A, Brignola C, et al. Effect of enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334(24):1557-60.
Benjamin J et al. Glutamine and Whey Protein Improve Intestinal Permeability and Morphology in Patients with Crohn's Disease: A Randomized Controlled Trial. Dig Dis Sci. 2011 Oct 26. [Epub ahead of print]
Bentz S, Hausmann M, et al. Clinical relevance of igg antibodies against food antigens in Crohn’s disease: a double-blind cross-over diet intervention study. Digestion 2010;81:252-64.
Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003;98(8):1797-801.
Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011;106:731-6.
Biasco G et al. Folate and prevention of colorectal cancer in ulcerative colitis. Eur J Cancer Prev. 2005 Aug;14(4):395-8.
Boznanska P, Wichan P, et al. 24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis. Pol Merkur Lekarski 2007;22(131):369-72 [in Polish].
Braunwald E. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001.
Brown AC, Roy M. Does evidence exist to include dietary therapy in the treatment of Crohn's disease? Expert Rev Gastroenterol Hepatol 2010;4(2):191-215.
Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002;47(10):2336-48.
Buyse J et al. Dietary L-carnitine supplementation enhances the lipopolysaccharide-induced acute phase protein response in broiler chickens. Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):154-9. Epub 2007 May 3.
Campos FG, Waitzberg DL, et al. Pharmacological nutrition in inflammatory bowel diseases. Nutr Hosp. 2003 Mar;18(2):57-64.
Chambers ES et al. The impact of vitamin D on regulatory T cells. Curr Allergy Asthma Rep. 2011 Feb;11(1):29-36.
Chan SSM, Luben R, et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther 2011;34:649-55.
Chin J. Intestinal microflora: negotiating health outcomes with the warring community within us. Asia Pac J Clin Nutr. 2004;13(suppl):S24-S25.
Chojnacki C, Wisniewska-Jarosinska M, et al. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 2011;62(3):327-34.
Colombel JF, Loftus EV Jr, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126;19-31.
Coogan PF, Rosenberg L. The use of folic acid antagonists and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 2007;16(10):1111-9.
Cosnes J. Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies? Dig Dis 2009;27:516-21.
Danelli P, Bartolucci C, et al. Surgical options in the treatment of perianal Crohn's disease [in Italian]. Ann Ital Chir. 2003 Nov;74(6):635-40.
de Moreno de Leblanc A et al. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. SRN Gastroenterol. 2011;2011:892971. Epub 2011 Feb 8.
Deckelbaum RJ et al. The omega-3 Fatty Acid nutritional landscape: health benefits and sources. J Nutr. 2012 Mar;142(3):587S-91S. Epub 2012 Feb 8.
Den Hond E, Hiele M, et al. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr 1999;23(1):7-11.
Di Sabatino A, Morera R, et al. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 2005;22(9):789-94.
Dinleyici Ec et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther. 2012 Feb 16. [Epub ahead of print]
Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 2004;99(11):2178-85.
Elahi B, Nikfar S, et al. On the benefit of probiotics in the management of pouchitis in patients that underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008;53(5):1278-84.
Esaki M, Matsumoto T, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to ﬁndings determined by intra-operative enteroscopy. Scand J Gastroenterol 2005;40:1431-7.
Etzel JP et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011 Jan 13. [Epub ahead of print]
Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004 May;10(3):286-99.
Feller ER, Ribaudo S, et al. Gynecologic aspects of Crohn's disease. Am Fam Physician. 2001 Nov 15;64(10):1725-8.
Fernandez-Miranda C, Martinez Prieto M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C-->T and 1298A-->C mutations in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2005 Jul;97(7):497-504.
Fife J et al. Folic acid supplementation and colorectal cancer risk: a meta-analysis. Colorectal Dis. 2011 Feb;13(2):132-7. doi: 10.1111/j.1463-1318.2009.02089.x.
Fujimori S, Tatsuguchi A, Gudis K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22(8):1199-204.
Furrie E, Macfarlane S, et al. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut. 2004 Jan;53(1):91-8.
Garcia Vilela E et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 2008;43(7):842-8.
Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000a;54(6):514-21.
Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000b;6(2):77-84.
Gerhardt H, Seifert F, et al. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001;39:11-7 [in German].
Giaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diets for Crohn's disease. Aliment Pharmacol Ther 1991;5(2):115-25.
Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2006;25:19-37.
Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Feb;17(3):307-20.
Golias C et al. Physiology and pathophysiology of selectins, integrins, and IgSF cell adhesion molecules focusing on inflammation. A paradigm model on infectious endocarditis. ll Commun Adhes. 2011 Jun;18(3):19-32. Epub 2011 Sep 5.
Gupta I, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2:37-43.
Gupta I, Parihar A, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67:391–5.
Haden ST, Glowacki J et al. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int. 2000 Jun;66(6):414-8.
Hanai H, Iida T, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(12):1502-6.
Hanai H, Kanauchi O, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004;13(5):643-7.
Harpavat M, Keljo DJ et al. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol. 2004 Mar;38(3):218-24.
Hawthorne AB, Daneshmend TK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33(7):922-8.
Head KA et al. Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003 Aug;8(3):247-83.
Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn's disease with an unrefined-carbohydrate, fiber-rich diet. Br Med J 1979;ii:764-6.
Heckers H, Melcher FW, et al. Chemically prepared fats and Crohn disease: a pilot study of the occurrence of trans-fatty acids in the subcutaneous tissue of Crohn patients in comparison with healthy controls as a parameter of long-term fat intake. Z Gastroenterol. 1988;26(5):259-64.
Hengstermann S et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr. 2008 Aug;27(4):571-8. Epub 2008 Mar 7.
Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57(11):1518-23.
Hillier K et al. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991;32(10):1151-5.
Hinks IJ, Inwards KD, Lloyd B, Clayton B. Reduced concentration of selenium in mild Crohn's disease. J Clin Pathol 1988;41:198-201.
Holt PR et al. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005 Nov;50(11):2191-3.
Holtmeier W, Zeuzem S, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011;17(2):573-82.
Homik J, Suarez-Almazor ME, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;(2):CD000952.
Hou JK et al. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011 Apr;106(4):563-73.
Hwang JM et al. Surgery for inflammatory bowel disease. World J Gastroenterol. 2008 May 7;14(17):2678-90.
Ibrahim A et al. Dietary α-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Nutrition. 2012 Jan 18. [Epub ahead of print]
Ishikawa H et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011;84(2):128-33. Epub 2011 Apr 28.
Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-G17.
Iwami D et al. Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells. Int Immunopharmacol. 2011 Mar;11(3):384-9. Epub 2010 Dec 18.
Jahnsen J, Falch JA, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37(2):192-9.
Jansen G et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications ofr combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum. 2004 Jul;50(7):2130-9
Johe PD, Osterud B. The in vivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise. J Pineal Res 2005;39:324–330.
Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005;21:921–31.
Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Long-term maintenance of remission by personalized food exclusion diets. Dig Dis Sci 1987;32(12 Suppl):100S--7S.
Jorgensen SP, Agnholt J, et al. Clinical trial:Vitamin D3 treatment in Crohn's disease---A randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010;32:377-83.
Jowett SL, Seal CJ, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004;53(10):1479-84.
Kaplan GG, Hubbard J, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010;105(11):2412-9.
Kappelman MD, Horvath-Puho E, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011;60:937–43.
Karimi O, Peña AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: A pilot study. Drugs Today (Barc) 2005;41(7):453-9.
Kim DH et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010 Nov;21(11):1919-30. Epub 2010 Sep 5.
Koutroubakis IE, Malliaraki N, et al. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004 Sep;49(9):1433-7.
Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(6):266-72.
Krasinski SD, Russell RM et al. The prevalence of vitamin K deficiency in chronic gastrointestinal disorders. Am J Clin Nutr 1985;41(3):639-43.
Kruidenier L, Kuiper I, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003 Sep;201(1):28-36.
Kruschewski M, Perez-Canto S et al. [Protective effect of glutamine on microcirculation of the intestine in experimental colitis]. Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):229-31.
Kuroki F, Matsumoto T, et al. Selenium is depleted in Crohn's disease on enteral nutrition. Dig Dis. 2003;21(3):266-70.
Kuwabara A, Tanaka K, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int 2009;20(6):935-42.
Langmead L et al. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004b Mar 1;19(5):521-7.
Langmead L et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004a Apr 1;19(7):739-47.
Lavasani S et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010 Feb 2;5(2):e9009.
Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(7):308-15
Lorenz-Meyer H, Bauer P, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease: a randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol. 1996;31:778-85.
Mahmood A, Needham J, et al. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005;17:739-44.
Maldonado MD, Calvo JR. Melatonin usage in ulcerative colitis: a case report. J Pineal Res 2008;45(3):339-40.
Malik T, Mannon P. Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci 2012;S4:1172-89.
Malolepszy J, Kuczymska-Sekieta K, Chachaj W. Sodium cromoglycate therapy in ulcerative colitis. Acta Allergol 1977;13:82–86.
Matters GL et al. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008 Apr;5(2):179-87.
McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010 May 14;16(18):2202-22.
McNamara DA, Brophy S, Hyland JM. Perianal Crohn’s disease and infliximab therapy. Surgeon. 2004 Oct;2(5):258-63.
Meister D, Bode J, et al. Anti-inflammatory effects of enteral diet components on Crohn's disease-affected tissues in vitro. Dig Liver Dis. 2002 Jun;34(6):430-8.
Miheller P et al. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol. 2010 Nov 28;16(44):5536-42.
Miheller P, Muzes G, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009;15:1656-1662.
Mikhailova TL et al. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther. 2011 Nov;34(9):1088-97.
Mitamura T, Sakamoto S et al. The more an ulcerative colitis is repeated, the more the risk of colorectal carcinogenesis is increased in mice. Anticancer Res. 2002 Nov-Dec;22(6C):3955-61.
Mortimore M and Florin TH. A role for B₁₂ in inflammatory bowel disease patients with suppurative dermatoses? An experience with high dose vitamin B₁₂ therapy. J Crohns Colitis. 2010 Oct;4(4):466-70. Epub 2010 Mar 21.
Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs. 2002;62(11):1689-705.
Nakajima S, Iijima H, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition 2011;27(10):1023-8.
Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol. 2004 Dec;13(4):309-16.
Newman WG et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011 Jun;12(6):815-26. Epub 2011 May 3.
Ockenga J et al. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr. 2005 Nov;59(11):1302-9.
Ojuawo A and Keith L. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med. 2002 Sep-Oct;48(9-10):116-9.
Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: A double-blind placebo-controlled study. Phytomedicine 2007;14(2-3):87-95.
Ooi JH et al. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Aspects Med. 2012 Feb;33(1):77-82. Epub 2011 Nov 6.
Oussalah A et al. ta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther. 2011 Nov;34(10):1173-84. doi: 10.1111/j.1365-2036.2011.04864.x. Epub 2011 Oct 3.
Papa A, Santoliquido A, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005 Nov 1;22(9):839-46.
Patel V, Macdonald JK, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009 Oct 7;(4):CD006884.
Phang M, Lazarus S, Wood LG, Garg M Diet and thrombosis risk: nutrients for prevention of thrombotic disease. Semin Thromb Hemost 2011;37(3):199-208.
Phelip JM et al. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Feb;14(2):242-8.
Pitcher MCL, Cummings JH. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut 1996;39:1-4.
Preiss JC et al. Use of methotrexate in patients with inflammatory bowel disease. Clin Exp Rheumatol. 2010 Sep-Oct;28 (5 Suppl 61):S151-5
Rakhimova OIu . Use of melatonin in combined treatment for inflammatory bowel diseases. Ter Arkh 2010;82(12):64-8 [in Russian].
Riordan AM, Hunter JO, et al. Treatment of active Crohn's disease by exclusion diet: East Anglian Multicentre Controlled Trial. Lancet 1993;342:1131-4.
Roblin X, Germain E, et al. Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients [in French]. Rev Med Interne. 2006 Feb;27(2):106-10.
Roediger WE. Decreased sulphur aminoacid intake in ulcerative colitis. Lancet 1998;351(9115):1555.
Roediger WEW, Moore J, Babidge W. Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 1997;42:1571-9.
Rogler G, Scholmerich J. Extraintestinal manifestations of inflammatory bowel disease [in German]. Med Klin (Munich). 2004 Mar 15;99(3):123-30.
Rogler G. Prebiotics and probiotics in ulcerative colitis: where do we stand? Digestion. 2011;84(2):126-7. Epub 2011 Apr 15.
Ross E. The role of marine fish oils in the treatment of ulcerative colitis. Nutr Rev. 1993;51(2):47-9.
Rowan FE, Docherty NG, Coffey JC, O'Connell PR. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br J Surg 2009;96(2):151-8.
Ruffolo C et al. Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire. J Gastrointest Surg. 2010 Jan;14(1):24-31. Epub 2009 Nov 10.
Rutgeerts P, Löfberg R, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–5.
Sakamoto N et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005 Feb;11(2):154-63.
Sartor RB. Efficacy of probiotics for the management of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011 Sep;7(9):606-8.
Sato S, Sasaki I, et al. Management of urinary complications in Crohn's disease. Surg Today. 1999;29(8):713-7.
Scholz D. The role of nutrition in the etiology of inflammatory bowel disease. Curr Probl Pediatr Adolesc Health Care. 2011 Oct;41(9):248-53.
Segain JP, Raingeard de la Bletiere D, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000 Sep;47(3):397-403.
Sengupta K et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011 Aug;354(1-2):189-97. Epub 2011 Apr 11.
Shakeri A et al. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int. 2010 Oct;14(4):498-504.
Sido B, Seel C, Hochlehnert A, et al. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? Dig Dis Sci 2006;51(12):2170-9.
Siffledeen JS, Siminoski K, et al. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol. 2003 Aug;17(8):473-8.
Simopoulos AP. Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev Nutr Diet. 2011;102:10-21. Epub 2011 Aug 5.
Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002 Oct;56(8):365-79.
Smith JP, Bingaman SI, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci 201156:2088-97.
Smith JP, Stock H, Bingaman S, et al. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol 2007;102:820-8.
Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99(1):97-101.
Sonoda K, Ikeda S, et al. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 2004;39(10):948-54.
Srirajaskanthan R, Winter M, et al. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2005 Jul;17(7):697-700.
Stefanini GF et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol. 1995 Jun;30(6):535-41.
Steinhart AH et al. Nutrition in inflammatory bowel disease. Curr Opinion Gastroenterol. 1997;13(2):140-5.
Stenson WF et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992 Apr 15;116(8):609-14.
Straub RH, Scholmerich J, et al. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases: substitutes of adrenal and sex hormones. Z Rheumatol. 2000;59(suppl 2):II/108-18.
Tavarela VF. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct;20(suppl 4):50-3.
Taylor RA et al. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev. 2011 Jun;16(2):152-6.
Teahon K, Smethurst P, et al. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology. 1991 Jul;101(1):84-9.
Terry PD, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm Bowel Dis 2009;15:134-40.
Thomas S et al. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011 Dec;301(6):G1083-92. Epub 2011 Sep 8.
Tighe MP, Cummings JR, Afzal NA. Nutrition and inflammatory bowel disease: primary or adjuvant therapy. Curr Opin Clin Nutr Metab Care. 2011 Sep;14(5):491-6.
Trebble TM, Arden NK, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr. 2004 Nov;80(5):1137-44.
Trebble TM, Stroud MA, et al. High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial. Br J Nutr. 2005 Aug;94(2):253-61.
Triggs CM, Munday K, et al. Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat Res 2010;690(1-2):123-38.
Tsai F and Coyle WJ. The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroenterol Rep. 2009 Aug;11(4):307-13.
Tursi A et al. h prevalence of celiac disease among patients affected by Crohn's disease. Inflamm Bowel Dis. 2005 Jul;11(7):662-6.
Uchiyama K et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Oct;16(10):1696-707.
Vagianos K et al. tion assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007 Jul-Aug;31(4):311-9.
Van Den Bogaerde J, Cahill J, et al. Gut mucosal response to food antigens in Crohn's disease. Aliment Pharmacol Ther 2002;16(11):1903-15.
Vermeire S, Peeters M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7(1):8-15.
Vieira EL et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem. 2011 Jun 8. [Epub ahead of print]
Wang TT, Dabbas B, Laperrier D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta-2 innate immune pathway defective in Crohn disease. J Biol Chem 2010;285(4):2227-31.
Watanabe O et al. Enteral nutrition decreases hospitalization rate in patients with Crohn's disease. J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S134-7.
Wiese DM et al. The effects of an oral supplement enriched with fish oil, prebiotics, and antioxidants on nutrition status in Crohn's disease patients. Nutr Clin Pract. 2011 Aug;26(4):463-73.
Wright R, Truelove SC. A controlled therapeutic trial of various diets in ulcerative colitis. Br Med J 1965;2:138-41.
Xu CT, Meng SY et al. Drug therapy for ulcerative colitis. World J Gastroenterol. 2004 Aug 15;10(16):2311-7.
Yakut M et al. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med. 2010 Aug;21(4):320-3. Epub 2010 Jun 8.
Yamamoto T, Nakahigashi M, et al. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: A prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther 2007;25:67-72.
Yuan Y et al. Protective effects of L-carnitine on intestinal ischemia/reperfusion injury in a rat model. J Clin Med Res. 2011 Apr 4;3(2):78-84
Zezos P, Papaioannou G, et al. Hyperhomocysteinemia in ulcerative colitis is related to folate levels. World J Gastroenterol. 2005 Oct 14;11(38):6038-42.
Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Netherlands J Med 2007;65(11):411--18.
Zintzaras E. Genetic variants of homocysteine/folate metabolism pathway and risk of inflammatory bowel disease: a synopsis and meta-analysis of genetic association studies. Biomarkers. 2010 Feb;15(1):69-79.